Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge

Kim, Joo Young; Jeon, Eun Seok; Lim, Byung Kwan; Kim, Sun Mi; Chung, Sun Ku; Kim, Jong Mook; Park, Sang Ick; Jo, Inho; Nam, Jae Hwan

doi:10.1016/j.vaccine.2004.10.008

Cited by 36 publications

(20 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[4][5][6] So far, there is no efficient vaccines or therapeutic reagents against CVB3-induced myocarditis in clinic. [7][8][9][10][11][12][13] Therefore, there is an obvious need to develop a new and efficient vaccine.…”

Section: Introductionmentioning

confidence: 99%

Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis

Chai

Yan²,

Xu³

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis

Chai

Yan²,

Xu³

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Since that time, several types of candidate vaccine against CVB3 have been developed. A subunit vaccine containing the capsid protein (Fohlman et al 1990) and several DNA vaccines (Henke et al 2001;Kim et al 2005Kim et al , 2009) have shown protective effects after lethal dose challenge. Several attenuated virus variants have also been developed to protect against CVB3-induced diseases (Landau et al 1990; Knowlton et al 1996;Zhang et al 1997).…”

Section: Introductionmentioning

confidence: 99%

Inoculation of the attenuated Coxsackievirus B3 Sabin3-like strain induces a protection against virulent CVB3 Nancy and CVB4 E2 strains in Swiss mice by both oral and intraperitoneal routes

et al. 2013

View full text Add to dashboard Cite

Abstract:We have previously addressed the question of whether the attenuating mutations of domain V of the Poliovirus IRES were specific for a given genomic context or whether they could be extrapolated to a genomic related virus, the Coxsackievirus B3 (CVB3). Accordingly, we have described that Sabin3-like mutation (U 473 →C) introduced in the CVB3 genome led to a defective mutant with a serious reduction in translation efficiency. In this study, we assessed the protection provided by the Sabin3-like mutant against CVB3 infection. For this purpose, we analyzed, in vivo, the Sabin3-like phenotype in Swiss mice inoculated with CVB3 and CVB4 E2 prototype strains either by oral or intraperitoneal (i.p) routes and explored the capacity of this mutant to act as a vaccine vector after the challenge. The Sabin3-like RNA was detected by semi-nested PCR in different organs: heart, pancreas and intestine at 10 days post-inoculation with both oral and i.p routes. Additionally, we did not observe any histological alterations in heart and intestine tissues. RNA was detected in the different organs of all mice immunized with the Sabin3-like strain and challenged with either CVB3 or CVB4 E2 by oral route at 7 days post-challenge. In contrast, no histological alteration of heart or pancreas tissues was observed after challenge with both wild-strains. Interestingly, the detection of viral RNA in heart, pancreas and intestine of mice immunized by i.p route was negative at 7 days post-challenge with CVB3 and CVB4 E2, and mice were protected from myocarditis and pancreatitis.

show abstract

“…Infection by coxsackievirus B3 (CVB3), one of the enteroviruses, is thought to be the most common cause of myocarditis because 5-50% of myocarditis and DCM is attributed to it [4]. However, there are no direct therapeutic reagents in clinical use that target these viruses, although some studies have demonstrated effective candidate vaccines for CVB3 in a murine model [5,6].…”

Section: Introductionmentioning

confidence: 99%

Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model

et al. 2008

Self Cite

View full text Add to dashboard Cite

Coxsackieviruses are important human pathogens that induce myocarditis and pancreatitis. However, there are no vaccines or therapeutic reagents for their clinical treatment. Although RNA interference (RNAi)-based approaches to the prevention of viral production have been developed recently, limitations to the in vivo delivery systems and variations in the viral target sequences still hamper the strategy. In this study, to overcome these limitations, we have constructed recombinant lentivirus-delivered short hairpin RNAs (shRNAs) against sequences in highly conserved cis-acting replication element (CRE) within the 2C protein of coxsackievirus B3 (CVB3), designated MET-2C. A recombinant lentivirus, designated Met-2C lenti, was constructed that contains the MET-2C sequence, which acts as a shRNA. Met-2C lenti clearly reduced viral production in CVB3-infected cells in vitro. Moreover, the mice injected intraperitoneally with Met-2C lenti had significant reductions in viral titers, viral myocarditis, and proinflammatory cytokines after challenge with CVB3, compared with those in GFP lenti infected control mice. Moreover, Met-2C lenti improved survival rate compared with that of the GFP lenti infected control group. Therefore, Met-2C lenti is potentially a clinical therapeutic agent for the treatment of viral myocarditis.

show abstract

Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge

Cited by 36 publications

References 24 publications

Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis

Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis

Inoculation of the attenuated Coxsackievirus B3 Sabin3-like strain induces a protection against virulent CVB3 Nancy and CVB4 E2 strains in Swiss mice by both oral and intraperitoneal routes

Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model

Contact Info

Product

Resources

About